Monday, February 05, 2024 8:03:48 AM
Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024
Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
Transaction Overview
Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. The purchase price represents a premium of 16.5% to the closing price of Catalent’s common stock as of February 2, 2024, the last trading day prior to this announcement, and a 47.5% premium to the 60-day volume-weighted average price as of February 2, 2024.
In addition, the purchase price represents a premium of 39.1% to the closing price of Catalent’s common stock on August 28, 2023, the last trading day prior to Catalent’s announcement that its Board of Directors formed a Strategic and Operational Review Committee to conduct a review of Catalent’s business, strategy and operations, as well as Catalent’s capital-allocation priorities with a view towards maximizing value for all Catalent stockholders.
Of Catalent’s more than 50 global sites, Novo Holdings intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk (CPH: NOVO), in which Novo Holdings has a controlling interest, shortly after the closing of the merger. These three sites are located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium.
This transaction is aligned with Novo Holdings’ strategy of investing in established life science companies with strong long-term potential.
Alessandro Maselli, President and Chief Executive Officer of Catalent, said: “Over the past several years, Catalent has built a comprehensive end-to-end offering of services and capabilities to drive innovation in the healthcare system and improve patient outcomes. This transaction is a testament to our team’s hard work and dedication to this mission, and I am incredibly excited for this next step in our journey. We look forward to benefiting from Novo Holdings’ significant resources to accelerate investment in our business and enhance key offerings as we continue to offer premium development and manufacturing solutions for pharma and biotech customers.”
John Greisch, Executive Chair of the Catalent Board and Chair of the Strategic and Operational Review Committee, said: “This transaction delivers significant, certain and premium value to our stockholders. Novo Holdings believes in our vision and will provide Catalent with a strong foundation as we continue developing, manufacturing and supplying top products.”
Novo Holdings has a proven track record of successfully investing in the life sciences sector. Importantly, Novo Holdings’ purpose is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Kasim Kutay, CEO of Novo Holdings, said: “We are excited to partner with Catalent as it enters a new phase of growth and accelerates its mission to develop, manufacture and supply products that help people live better and healthier lives. With our expertise and track record of investing in high quality life sciences businesses, we believe Catalent is a very good strategic fit. We are excited to support the Company’s stakeholders in the years ahead, especially employees and customers as they work to develop new products to benefit patients. As engaged investors committed to productive relationships with all our partners, we look forward to working with the Catalent team to realise the Company’s full potential.
Importantly, our acquisition of Catalent is aligned with our mandate to invest in high quality life sciences companies for the benefit of the Novo Nordisk Foundation’s mission and philanthropic causes.”
Marc Steinberg, Partner at Elliott Investment Management L.P., said: “As a significant investor in Catalent, Elliott fully supports the transaction announced today. We believe that this transaction, which is the culmination of a process led by the Strategic and Operational Review Committee of the Catalent Board, clearly maximizes value for Catalent stockholders. We commend Catalent’s Board and management team for delivering this outstanding outcome.”
Transaction Details
The merger is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including approval by Catalent stockholders and receipt of required regulatory approvals. The transaction is not subject to any financing contingency.
Following an evaluation of possible value-maximizing alternatives, the Catalent Board unanimously determined that the transaction with Novo Holdings, which delivers a premium and certain cash value, is in the best interest of Catalent. Accordingly, the Catalent Board unanimously recommends that Catalent stockholders vote in favor of the merger.
In addition, Elliott Investment Management L.P. and certain of its affiliates have entered into a support agreement pursuant to which they have agreed to vote their shares of Catalent common stock in favor of the merger.
Following the closing of the merger, shares of Catalent will no longer trade on the New York Stock Exchange and Catalent will become a private company.
Second Quarter 2024 Financial Results
Catalent’s second quarter 2024 earnings results are expected to be issued on February 9, 2024. In light of the announced transaction, Catalent will not host an earnings conference call. Catalent’s second quarter 2024 earnings press release will be available on its investor relations website at http://investor.catalent.com .
Advisors
Citi and J.P. Morgan are acting as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor to Catalent and Jones Day is serving as legal advisor to the Catalent Board of Directors. Morgan Stanley is acting as financial advisor to Novo Holdings and Goodwin Procter LLP is serving as legal advisor to Novo Holdings.
About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.
As of year-end 2022, Novo Holdings had total assets of EUR 108 billion.
www.novoholdings.dk
About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
www.novonordiskfonden.dk/en
About Catalent
Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.
Recent SNOW News
- Snowflake to Announce Financial Results for the First Quarter of Fiscal 2025 on May 22, 2024 • Business Wire • 04/29/2024 03:34:00 PM
- Snowflake Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 29, 2024 to Discuss Your Rights - SNOW • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Snowflake Launches Arctic: The Most Open, Enterprise-Grade Large Language Model • Business Wire • 04/24/2024 01:01:00 PM
- Lost Money on Snowflake Inc.(SNOW)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 04/19/2024 09:55:00 AM
- Investors who lost money on Snowflake Inc.(SNOW) should contact The Gross Law Firm about pending Class Action - SNOW • PR Newswire (US) • 04/16/2024 09:55:00 AM
- The Gross Law Firm Notifies Snowflake Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SNOW • PR Newswire (US) • 04/12/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Snowflake Inc.(SNOW) Shareholders • PR Newswire (US) • 04/09/2024 10:05:00 AM
- Investors in Snowflake Inc. Should Contact The Gross Law Firm Before April 29, 2024 to Discuss Your Rights - SNOW • PR Newswire (US) • 04/05/2024 09:45:00 AM
- The Gross Law Firm Notifies Snowflake Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 04/02/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 29, 2024 in Snowflake Inc. Lawsuit - SNOW • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Snowflake Revolutionizes Secure, Cross-Cloud Collaboration for High Value Business Outcomes with Snowflake Data Clean Rooms • Business Wire • 03/28/2024 01:01:00 PM
- Snowflake Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 29, 2024 to Discuss Your Rights - SNOW • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Snowflake Inc. Class Action: The Gross Law Firm Reminds Snowflake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 29, 2024 - SNOW • PR Newswire (US) • 03/22/2024 10:25:00 AM
- Snowflake Teams with NVIDIA to Deliver Full-Stack AI Platform for Customers to Transform Their Industries • Business Wire • 03/18/2024 10:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 04:15:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 03:43:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 02:08:40 PM
- The Gross Law Firm Reminds Snowflake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 29, 2024 - SNOW • PR Newswire (US) • 03/11/2024 09:45:00 AM
- Moore Law, PLLC Encourages Snowflake Inc. Investors to Contact Law Firm • PR Newswire (US) • 03/08/2024 11:55:00 PM
- Shareholders of Snowflake Inc. Should Contact The Gross Law Firm Before April 29, 2024 to Discuss Your Rights - SNOW • PR Newswire (US) • 03/07/2024 10:45:00 AM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/06/2024 12:50:05 AM
- Snowflake Partners with Mistral AI to Bring Industry-Leading Language Models to Enterprises Through Snowflake Cortex • Business Wire • 03/05/2024 02:01:00 PM
- DiCello Levitt LLP Announces Investor Class Action Lawsuit Filed Against Snowflake, Inc. (NYSE: SNOW) and Lead Plaintiff Deadline • PR Newswire (US) • 03/05/2024 01:00:00 PM
- Snowflake Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 29, 2024 to Discuss Your Rights - SNOW • PR Newswire (US) • 03/05/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:33:40 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM